Payment overview · 2025
General Payments
$245.31
13 reported records · 9 companies
Healthcare provider profile · identity verified
Ronald Mclendon, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · GRETNA, LA · NPI 1013151091
Verified facts
What the public records show
CMS Open Payments records show Ronald Mclendon, M.D. received $245.31 in general payments during 2025 across 13 reported records.
Lilly USA, LLC accounted for 21.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Qutenza, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Farxiga by this doctor in 2024.
Averitas Pharma Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QUTENZA as an associated drug or biological on 11743 records involving 7078 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Qutenza by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 260 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 533 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.92 | 21.2% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.29 | 16.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $34.64 | 14.1% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $27.49 | 11.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $23.44 | 9.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $20.34 | 8.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $16.75 | 6.8% | 1 | 2025 |
| Averitas Pharma Inc. | Unresolved — no canonical attribution shown | $15.23 | 6.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.21 | 6.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $245.31 | 13 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $74.93 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $51.92 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $35.03 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $27.49 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $16.75 | 1 | 2025 |
Source payment records
|
|||||
| QUTENZA Normalized: qutenza |
Drug | Averitas Pharma Inc. | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $15.21 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QUTENZA qutenza |
2025 | Qutenza | 2024 | 43 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
33 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Averitas Pharma Inc. Exact reporting entity; no affiliate inference |
2025 | QUTENZA open payments reported associated product |
CMS Open Payments — General Payments 11743 supporting records · 7078 recipient NPIs · example record 1248543069 |
Qutenza · 2024 Exact normalized brand match · 1 Part D row |
43 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
260 | 45 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
94 | 20 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
533 | 60 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1030 | 272 |
| Amlodipine Besylate | Amlodipine Besylate | 725 | 194 |
| Eliquis | Apixaban | 533 | 60 |
| Losartan Potassium | Losartan Potassium | 404 | 105 |
| Metformin Hcl | Metformin Hcl | 379 | 89 |
| Gabapentin | Gabapentin | 364 | 92 |
| Pantoprazole Sodium | Pantoprazole Sodium | 347 | 99 |
| Lisinopril | Lisinopril | 332 | 74 |
| Furosemide | Furosemide | 297 | 46 |
| Tamsulosin Hcl | Tamsulosin Hcl | 297 | 66 |
| Levothyroxine Sodium | Levothyroxine Sodium | 271 | 44 |
| Carvedilol | Carvedilol | 270 | 67 |
| Jardiance | Empagliflozin | 260 | 45 |
| Potassium Chloride | Potassium Chloride | 258 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 215 | 77 |
| Metoprolol Succinate | Metoprolol Succinate | 213 | 56 |
| Mirtazapine | Mirtazapine | 213 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 212 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 211 | 55 |
| Donepezil Hcl | Donepezil Hcl | 209 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 191 | 37 |
| Trazodone Hcl | Trazodone Hcl | 188 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 174 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 157 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 152 | 31 |
| Memantine Hcl | Memantine Hcl | 138 | 27 |
| Ozempic | Semaglutide | 137 | 29 |
| Levetiracetam | Levetiracetam | 131 | 24 |
| Famotidine | Famotidine | 130 | 34 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 130 | 29 |
| Myrbetriq | Mirabegron | 128 | 18 |
| Allopurinol | Allopurinol | 123 | 24 |
| Januvia | Sitagliptin Phosphate | 121 | 14 |
| Sertraline Hcl | Sertraline Hcl | 119 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 117 | 43 |
| Buspirone Hcl | Buspirone Hcl | 116 | 23 |
| Finasteride | Finasteride | 111 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 111 | 27 |
| Latanoprost | Latanoprost | 109 | 24 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 107 | 21 |
| Nifedipine Er | Nifedipine | 98 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 98 | 29 |
| Omeprazole | Omeprazole | 96 | 29 |
| Trulicity | Dulaglutide | 94 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 89 | 19 |
| Simvastatin | Simvastatin | 82 | 21 |
| Metformin Hcl Er | Metformin Hcl | 79 | 22 |
| Risperidone | Risperidone | 79 | 11 |
| Alendronate Sodium | Alendronate Sodium | 73 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 68 | 14 |
| Spironolactone | Spironolactone | 65 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 61 | 20 |
| Methocarbamol | Methocarbamol | 60 | 18 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 57 | 14 |
| Repatha Sureclick | Evolocumab | 57 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 56 | 22 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 55 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 51 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 50 | 24 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 50 | 50 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 19 |
| Montelukast Sodium | Montelukast Sodium | 47 | 15 |
| Tramadol Hcl | Tramadol Hcl | 47 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 19 |
| Tradjenta | Linagliptin | 46 | suppressed |
| Baclofen | Baclofen | 45 | suppressed |
| Brilinta | Ticagrelor | 45 | suppressed |
| Olanzapine | Olanzapine | 44 | suppressed |
| Qutenza | Capsaicin/Skin Cleanser | 43 | 24 |
| Clonidine Hcl | Clonidine Hcl | 42 | 16 |
| Entresto | Sacubitril/Valsartan | 42 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 13 |
| Methotrexate | Methotrexate Sodium | 40 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 37 | 13 |
| Aripiprazole | Aripiprazole | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 36 | suppressed |
| Meloxicam | Meloxicam | 36 | 18 |
| Novolog Flexpen | Insulin Aspart | 36 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Lidocaine | Lidocaine | 34 | 11 |
| Prednisone | Prednisone | 34 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 34 | suppressed |
| Amantadine | Amantadine Hcl | 33 | suppressed |
| Linzess | Linaclotide | 33 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 27 |
| Benztropine Mesylate | Benztropine Mesylate | 32 | suppressed |
| Colchicine | Colchicine | 32 | suppressed |
| Diazepam | Diazepam | 32 | suppressed |
| Gemtesa | Vibegron | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Rexulti | Brexpiprazole | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Ketoconazole | Ketoconazole | 30 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 30 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 27 | 24 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | 11 |
| Megestrol Acetate | Megestrol Acetate | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 26 | suppressed |
| Irbesartan | Irbesartan | 26 | suppressed |
| Levemir Flexpen | Insulin Detemir | 26 | suppressed |
| Timolol Maleate | Timolol Maleate | 26 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 24 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 24 | suppressed |
| Alprazolam | Alprazolam | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 20 |
| Glipizide | Glipizide | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 23 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 23 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Ezetimibe | Ezetimibe | 22 | suppressed |
| Isosorbide Dinit-Hydralazine | Isosorbide Dinit/Hydralazine | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 21 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 20 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 20 | suppressed |
| Easy Touch Safety Pen Needle | Pen Needle, Diabetic, Safety | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 20 | suppressed |
| Celecoxib | Celecoxib | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 19 | suppressed |
| Mounjaro | Tirzepatide | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 12 |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 18 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 16 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 16 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 15 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 15 | suppressed |
| Tiotropium Bromide | Tiotropium Bromide | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Humalog | Insulin Lispro | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Nystatin | Nystatin | 13 | 11 |
| Pen Needles | Pen Needle, Diabetic | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Enbrel | Etanercept | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 12 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 12 | suppressed |
| Methotrexate Sodium | Methotrexate Sodium/Pf | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Azithromycin | Azithromycin | 11 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Ingrezza | Valbenazine Tosylate | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $245.31 · 13 records | Lilly USA, LLC | ABRYSVO, BREZTRI, COMIRNATY, DUPIXENT, MOUNJARO, PREVNAR 20, QULIPTA, QUTENZA, REXULTI, The Cologuard Plus Collection Kit, UBRELVY, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error